On July 31, 2014, the FDA provided to congress the “anticipated details” of its draft Guidance describing its framework for Laboratory Developed Tests (LDTs) and Companion Diagnostics (CDx) guidance. In the FDA press release they indicated they were reinforcing their commitment to personalized medicine and taking “steps to help ensure the reliability of certain diagnostic tests.” As requested by Congress,…
